Preface
Special issue on personalized therapy in lung cancer
Translational Lung Cancer Research
2014;
3
(6)
:358-359
.
(19 December 2014)
AZD9291
Update on third-generation EGFR tyrosine kinase inhibitors
Translational Lung Cancer Research
2014;
3
(6)
:360-362
.
(19 December 2014)
Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?
Translational Lung Cancer Research
2014;
3
(6)
:363-364
.
(19 December 2014)
EGFR, EGFR TKI, and EMSI: a never-ending story
Translational Lung Cancer Research
2014;
3
(6)
:365-367
.
(19 December 2014)
Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance
Translational Lung Cancer Research
2014;
3
(6)
:368-369
.
(19 December 2014)
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor—resistant non-small cell lung cancer
Translational Lung Cancer Research
2014;
3
(6)
:370-372
.
(19 December 2014)
Ceritinib
Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer
Translational Lung Cancer Research
2014;
3
(6)
:373-375
.
(19 December 2014)
Ceritinib as a promising therapy for ALK related diseases
Translational Lung Cancer Research
2014;
3
(6)
:376-378
.
(19 December 2014)
Ceritinib—a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
Translational Lung Cancer Research
2014;
3
(6)
:379-381
.
(19 December 2014)
Gemcitabine-cisplatin plus necitumumab
Necitumumab: a new therapeutic option for squamous cell lung cancer?
Translational Lung Cancer Research
2014;
3
(6)
:382-383
.
(19 December 2014)
Onartuzumab plus erlotinib
A critical question for cancer therapy: what new targets exist?
Translational Lung Cancer Research
2014;
3
(6)
:384-388
.
(19 December 2014)
Targeting MET in NSCLC: looking for a needle in a haystack
Translational Lung Cancer Research
2014;
3
(6)
:389-391
.
(19 December 2014)
Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC
Translational Lung Cancer Research
2014;
3
(6)
:392-394
.
(19 December 2014)
Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?
Translational Lung Cancer Research
2014;
3
(6)
:395-396
.
(19 December 2014)
Docetaxel (DOC) and ramucirumab
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2nd-line metastatic NSCLC
Translational Lung Cancer Research
2014;
3
(6)
:397-399
.
(19 December 2014)
Nivolumab
Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?
Translational Lung Cancer Research
2014;
3
(6)
:400-402
.
(19 December 2014)
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
Translational Lung Cancer Research
2014;
3
(6)
:403-405
.
(19 December 2014)
MEDI4736
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
Translational Lung Cancer Research
2014;
3
(6)
:406-407
.
(19 December 2014)
A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer—the anti-PDL1 antibody—MEDI4736
Translational Lung Cancer Research
2014;
3
(6)
:408-410
.
(19 December 2014)
MK-3475
Reflections on immune checkpoint inhibition in non-small cell lung cancer
Translational Lung Cancer Research
2014;
3
(6)
:411-413
.
(19 December 2014)
News
Highlights in the 14th Central European Lung Cancer Conference (CELCC)
Translational Lung Cancer Research
2014;
3
(6)
:414-419
.
(19 December 2014)
Disclosure:
The focused issue “Personalized Therapy in Lung Cancer” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Na Zhang, Wen-Zhao Zhong and Yi-Long Wu served as the unpaid Guest Editors for the focused issue.
